Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTOK1D)

• Drug Name: AMP-PNP Drug Info
• Synonyms: Phosphoaminophosphonic acid-adenylate ester; gamma-Imino-ATP; ADENYLYL IMIDODIPHOSPHATE; AMPPNP; Adenyl imidodiphosphate; phosphoaminophosphonic acid-adenylate ester; 25612-73-1; adenyl-5'-yl imidodiphosphate; CHEBI:47785; App(NH)p; O(5')-(1,2-dihydroxy-2-phosphonoaminodiphosphoryl)adenosine; 5'-O-(hydroxy{[hydroxy(phosphonoamino)phosphoryl]oxy}phosphoryl)adenosine; [[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]amino]phosphonic acid; p(NH)Ppf; beta,gamma-Imido-ATP; beta,gamma-Imidoadenosine; Phosphoaminophosphonic Acid-Adenylate Ester

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 33113
  ChEBI ID: CHEBI:47785
  CAS Number: CAS 25612-73-1
  TTD Drug ID: DMTOK1D

Molecule-Related Drug Atlas

Drug(s) Targeting Stress-activated protein kinase JNK3 (JNK3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID25991433-Compound-A1	DM89LF0	N. A.	N. A.	Patented	[6]
PMID25991433-Compound-F2	DM37VIQ	N. A.	N. A.	Patented	[6]
7-azaindole derivative 1	DMQL5B7	N. A.	N. A.	Patented	[6]
7-azaindole derivative 5	DMV3H98	N. A.	N. A.	Patented	[6]
PMID25991433-Compound-P6	DMNDVC9	N. A.	N. A.	Patented	[6]
PMID25991433-Compound-J3	DM17P3F	N. A.	N. A.	Patented	[6]
PMID25991433-Compound-P1	DMD8AX6	N. A.	N. A.	Patented	[6]
PMID25991433-Compound-O3	DMVOWS5	N. A.	N. A.	Patented	[6]
PMID25991433-Compound-J2	DMZSOCK	N. A.	N. A.	Patented	[6]
7-azaindole derivative 3	DMQ7BV4	N. A.	N. A.	Patented	[6]

Drug(s) Targeting LCK tyrosine protein kinase (LCK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[7]
VX-680	DM93YKJ	Solid tumour/cancer	2A00-2F9Z	Phase 2	[7]
JNJ-26483327	DMSQ3AZ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
ISIS-CRP	DMQDUG4	Cardiovascular disease	BA00-BE2Z	Phase 1	[9]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[10]
Bisindolylmaleimide-I	DMOQJZC	Discovery agent	N.A.	Investigative	[10]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[11]
CI-1040	DMF3DZX	Discovery agent	N.A.	Investigative	[10]
BMS-536924	DMXJB4N	Discovery agent	N.A.	Investigative	[12]
KN-62	DMLZ89P	Discovery agent	N.A.	Investigative	[10]

Drug(s) Targeting Insulin-like growth factor I receptor (IGF1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Teprotumumab	DM4L59B	Graves disease	5A02.0	Approved	[13]
Mecasermin	DM1O3BY	Growth failure	LD2F.1Y	Approved	[14]
Somatomedin-1	DMZ9FAO	Hormone deficiency	5A61.1	Approved	[15]
OSI-906	DMHKZLF	Solid tumour/cancer	2A00-2F9Z	Phase 3	[16]
Rinfabate	DML9FD4	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[17]
MM-141	DM2RJ4D	Pancreatic cancer	2C10	Phase 2	[18]
TT-100	DMZE6Y9	Non-small-cell lung cancer	2C25.Y	Phase 2	[19]
AMG 479	DM0DRAZ	Breast cancer	2C60-2C65	Phase 2	[20]
VPI-2690B	DMUQZT4	Diabetic nephropathy	GB61.Z	Phase 2	[21]
AXL-1717	DMTQ1Y3	Solid tumour/cancer	2A00-2F9Z	Phase 2	[22]

Drug(s) Targeting Ephrin type-A receptor 2 (EPHA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CAR-T cells targeting EphA2	DMN3C2I	Malignant glioma	2A00.0	Phase 1/2	[23]
BT5528	DMYBKMV	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[24]
DS-8895	DM31VNC	Solid tumour/cancer	2A00-2F9Z	Phase 1	[25]
MEDI-547	DM3WP70	Solid tumour/cancer	2A00-2F9Z	Phase 1	[26]
MEDI-543	DM7Q1PF	Solid tumour/cancer	2A00-2F9Z	Preclinical	[27]
PMID23489211C20	DMDYC4J	Discovery agent	N.A.	Investigative	[28]
PMID19788238C66	DMCVJK9	Discovery agent	N.A.	Investigative	[29]
PMID21561767C8h	DMABZH6	Discovery agent	N.A.	Investigative	[30]

Drug(s) Targeting DNA repair protein RAD51 homolog 1 (RAD51)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CYT-0851	DME6NMJ	B-cell lymphoma	2A86	Phase 1/2	[31]

Drug(s) Targeting Glycogen synthase kinase-3 beta (GSK-3B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AMO-02	DMJRU3A	Myotonic dystrophy	8C71.0	Phase 2/3	[32]
LY2090314	DMTBFE4	Acute myeloid leukaemia	2A60	Phase 2	[33]
Lithium	DMZ3OU6	Bipolar disorder	6A60	Phase 2	[34]
Tideglusib	DME4LA1	Alzheimer disease	8A20	Phase 2	[35]
9-ING-41	DM57TY3	Myelofibrosis	2A20.2	Phase 2	[36]
Neu-120	DMXKOUC	Parkinson disease	8A00.0	Phase 1/2	[37]
KENPAULLONE	DMAGVXW	Discovery agent	N.A.	Patented	[38]
CHIR-99021	DMB8MNU	Allergic inflammation	4A80-4A85	Patented	[39]
TDZD-8	DMG6Q45	Malignant glioma	2A00.0	Patented	[40]
AR-A014418	DMUPN01	Ovarian cancer	2C73	Patented	[41]

Drug(s) Targeting Ephrin type-B receptor 2 (EPHB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BVD-523	DMNB4XK	Melanoma	2C30	Phase 2	[42]
SEphB4-HSA	DMD8RU0	Kaposi sarcoma	2B57	Phase 2	[43]
KO-947	DMZMSBI	Solid tumour/cancer	2A00-2F9Z	Phase 1	[42]
MK-8353	DMLCTI5	Solid tumour/cancer	2A00-2F9Z	Phase 1	[42]
PMID23489211C20	DMDYC4J	Discovery agent	N.A.	Investigative	[28]
PMID19788238C66	DMCVJK9	Discovery agent	N.A.	Investigative	[29]
SNEWIQPRLPQH	DMYUH62	Discovery agent	N.A.	Investigative	[44]

Drug(s) Targeting MAP kinase p38 (MAPK12)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SM-101	DMFX9O6	Idiopathic thrombocytopenic purpura	3B64.10	Approved (orphan drug)	[45]
VX-745	DMJAEG6	Alzheimer disease	8A20	Phase 2	[46]
ARRY-797	DMJ48AB	Dilated cardiomyopathy	BC43.0	Phase 2	[47]
KC706	DMBX6C7	Cardiovascular disease	BA00-BE2Z	Discontinued in Phase 2	[48]
SB 235699	DMNH8XU	Psoriasis vulgaris	EA90	Discontinued in Phase 1	[49]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[10]
Bisindolylmaleimide-I	DMOQJZC	Discovery agent	N.A.	Investigative	[10]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[11]
CI-1040	DMF3DZX	Discovery agent	N.A.	Investigative	[10]
KN-62	DMLZ89P	Discovery agent	N.A.	Investigative	[10]

Drug(s) Targeting DNA topoisomerase II beta (TOP2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dexrazoxane	DMD7X1O	Breast cancer	2C60-2C65	Approved	[50]
XK-469	DMVYO41	Solid tumour/cancer	2A00-2F9Z	Phase 1	[51]
XB-947	DM1UIOA	Solid tumour/cancer	2A00-2F9Z	Phase 1	[52]
A-62176	DM4WT7Z	N. A.	N. A.	Terminated	[53]
3'-THIO-THYMIDINE-5'-PHOSPHATE	DM5SM8X	Discovery agent	N.A.	Investigative	[2]

Drug(s) Targeting Bacterial Pantothenate kinase (Bact coaA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Coenzyme A	DM1I8LU	Discovery agent	N.A.	Investigative	[50]

Drug(s) Targeting Long transient receptor potential channel 4 (TRPM4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PIP2	DMOZV7N	Discovery agent	N.A.	Investigative	[54]
adenosine diphosphate	DMFUHKP	N. A.	N. A.	Investigative	[3]
decavanadate	DMLT1N3	Discovery agent	N.A.	Investigative	[55]
BTP2	DMNM63G	Discovery agent	N.A.	Investigative	[56]
9-phenanthrol	DMJFBQ1	Discovery agent	N.A.	Investigative	[57]

Drug(s) Targeting Mycobacterium Thymidine monophosphate kinase (MycB tmk)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetate Ion	DMD08RH	Discovery agent	N.A.	Investigative	[50]
2'-deoxythymidine triphosphate	DM9OEJT	Discovery agent	N.A.	Investigative	[50]
Deoxythymidine	DMR90HY	Discovery agent	N.A.	Investigative	[50]
Diphosphate	DMHY30B	Discovery agent	N.A.	Investigative	[50]
Thymidine-5'-Phosphate	DMKM6NQ	Discovery agent	N.A.	Investigative	[50]
P1-(5'-Adenosyl)P5-(5'-Thymidyl)Pentaphosphate	DMM4VWD	Discovery agent	N.A.	Investigative	[58]
3'-Azido-3'-Deoxythymidine-5'-Monophosphate	DMU08MN	Discovery agent	N.A.	Investigative	[50]
5-Hydroxymethyluridine-2'-Deoxy-5'-Monophosphate	DMWVCJ1	Discovery agent	N.A.	Investigative	[50]
CHLORODEOXYURIDINE	DMQT3WJ	Discovery agent	N.A.	Investigative	[59]
BROMODEOXYURIDINE	DM0D7LA	Discovery agent	N.A.	Investigative	[59]

Drug(s) Targeting DNA topoisomerase II (TOP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[60]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[61]
Teniposide	DMLW57T	Acute lymphoblastic leukaemia	2A85	Approved	[60]
Mitoxantrone	DMM39BF	Acute myelogenous leukaemia	2A41	Approved	[62]
Idarubicin	DMM0XGL	Acute myelogenous leukaemia	2A41	Approved	[60]
Epirubicin	DMPDW6T	Solid tumour/cancer	2A00-2F9Z	Approved	[60]
Lomefloxacin	DMVRH9C	Bacterial infection	1A00-1C4Z	Approved	[63]
Dexrazoxane	DMD7X1O	Breast cancer	2C60-2C65	Approved	[60]
Podofilox	DMT2EJP	Condyloma	1A95	Approved	[64]
Enoxacin	DMYTE6L	Acute gonococcal cervicitis		Approved	[65]

Drug(s) Affected By Cystic fibrosis transmembrane conductance regulator (CFTR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ivacaftor	DMZC1HS	Cystic fibrosis	CA25	Approved	[66]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[67]
Rhucin	DM3ADGP	Erectile dysfunction	HA01.1	Approved	[68]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[69]
Miglustat	DM5J64S	Niemann-Pick disease type C		Approved	[70]
Glibenclamide	DM8JXPZ	Diabetic complication	5A2Y	Approved	[71]
Milrinone	DM8TUPF	Congestive heart failure	BD10	Approved	[68]
Oxidized glutathione	DM9EQC0	Breast cancer	2C60-2C65	Approved	[5]
Glutathione	DMAHMT9	Human immunodeficiency virus infection	1C62	Approved	[5]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[72]

Drug(s) Affected By Casein kinase II subunit alpha (CSNK2A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[73]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[74]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[75]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[74]
Adenosine triphosphate	DM79F6G	Malnutrition	5B50-5B71	Approved	[76]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[77]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[78]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[79]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[80]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[81]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial Pantothenate kinase (Bact coaA)	TTSEOPJ	COAA_ECOLI	Inhibitor	[2]
DNA repair protein RAD51 homolog 1 (RAD51)	TTC0G1L	RAD51_HUMAN	Inhibitor	[2]
DNA topoisomerase II (TOP2)	TT0IHXV	TOP2A_HUMAN; TOP2B_HUMAN	Inhibitor	[2]
DNA topoisomerase II beta (TOP2B)	TT4NVEM	TOP2B_HUMAN	Inhibitor	[2]
Ephrin type-A receptor 2 (EPHA2)	TTRJB2G	EPHA2_HUMAN	Inhibitor	[2]
Ephrin type-B receptor 2 (EPHB2)	TTKPV6O	EPHB2_HUMAN	Inhibitor	[2]
Glycogen synthase kinase-3 beta (GSK-3B)	TTRSMW9	GSK3B_HUMAN	Inhibitor	[2]
Insulin-like growth factor I receptor (IGF1R)	TTHRID2	IGF1R_HUMAN	Inhibitor	[2]
LCK tyrosine protein kinase (LCK)	TT860QF	LCK_HUMAN	Inhibitor	[2]
Long transient receptor potential channel 4 (TRPM4)	TTJ2HKA	TRPM4_HUMAN	Inhibitor (gating inhibitor)	[3]
MAP kinase p38 (MAPK12)	TTYT93M	MK12_HUMAN	Inhibitor	[2]
Mycobacterium Thymidine monophosphate kinase (MycB tmk)	TT5B8AX	KTHY_MYCTU	Inhibitor	[2]
Stress-activated protein kinase JNK3 (JNK3)	TT056SO	MK10_HUMAN	Inhibitor	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Casein kinase II subunit alpha (CSNK2A1)	OT9T8WQM	CSK21_HUMAN	Protein Interaction/Cellular Processes	[4]
Cystic fibrosis transmembrane conductance regulator (CFTR)	OT6B22QH	CFTR_HUMAN	Gene/Protein Processing	[5]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2456).
• [2] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [3] Intracellular nucleotides and polyamines inhibit the Ca2+-activated cation channel TRPM4b. Pflugers Arch. 2004 Apr;448(1):70-5.
• [4] Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease. Nat Commun. 2021 Aug 3;12(1):4671. doi: 10.1038/s41467-021-24878-z.
• [5] Reversible silencing of CFTR chloride channels by glutathionylation. J Gen Physiol. 2005 Feb;125(2):127-41. doi: 10.1085/jgp.200409115. Epub 2005 Jan 18.
• [6] c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
• [7] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [8] National Cancer Institute Drug Dictionary (drug id 596693).
• [9] The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
• [10] Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
• [11] Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
• [12] Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
• [13] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [14] IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer. Virchows Arch. 2003 Aug;443(2):139-45.
• [15] 2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006).
• [16] Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family... Bioorg Med Chem Lett. 2010 Apr 15;20(8):2452-5.
• [17] Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3. Drugs R D. 2005;6(2):120-7.
• [18] MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther. 2014 Feb;13(2):410-25.
• [19] BiPar Sciences Co-founder Reunites Management Team At TriAct Therapeutics to Advance Clinical Stage Cancer Programs. TriAct Therapeutics. Sept. 10, 2009.
• [20] Clinical pipeline report, company report or official report of Amgen (2009).
• [21] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [22] Clinical Phase I study with an Insulin-like Growth Factor-1 receptor inhibitor: experiences in patients with squamous non-small cell lung carcinoma. Acta Oncol. 2011 Apr;50(3):441-7.
• [23] ClinicalTrials.gov (NCT02575261) CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients
• [24] MMAE Delivery Using the Bicycle Toxin Conjugate BT5528. Mol Cancer Ther. 2020 Jul;19(7):1385-1394.
• [25] Clinical pipeline report, company report or official report of Daiichi Sankyo.
• [26] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1822).
• [27] Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer. Cancer Biol Ther. 2010 Dec 15;10(12):1306-14.
• [28] Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem. 2013 Apr 11;56(7):2936-47.
• [29] Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem. 2009 Oct 22;52(20):6433-46.
• [30] Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3743-8.
• [31] National Cancer Institute Drug Dictionary (drug name CYT0851).
• [32] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [33] Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
• [34] The GSK3 kinase inhibitor lithium produces unexpected hyperphosphorylation of -catenin, a GSK3 substrate, in human glioblastoma cells. Biol Open. 2018 Jan 26;7(1):bio030874.
• [35] Evidence for irreversible inhibition of glycogen synthase kinase-3beta by tideglusib. J Biol Chem. 2012 Jan 6;287(2):893-904.
• [36] 9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer. Sci Rep. 2019 Dec 27;9(1):19977.
• [37] Company report (Neurim Pharmaceuticals)
• [38] 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.
• [39] Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95.
• [40] Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3beta inhibitors through virtual screening. Bioorg Med Chem Lett. 2012 Dec 1;22(23):7232-6.
• [41] Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models. Eur J Med Chem. 2009 Jun;44(6):2361-71.
• [42] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [43] National Cancer Institute Drug Dictionary (drug name SEphB4-HSA).
• [44] Three-dimensional structure of the EphB2 receptor in complex with an antagonistic peptide reveals a novel mode of inhibition. J Biol Chem. 2007 Dec 14;282(50):36505-13.
• [45] Agents in development for the treatment of diabetic nephropathy. Expert Opin Emerg Drugs. 2008 Sep;13(3):447-63.
• [46] P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis. J Inflamm (Lond). 2008 Dec 4;5:22.
• [47] Array BioPharmas ARRY-797 Meets Primary Endpoint in Clinical Proof of Concept Trial in Osteoarthritis Patients Whose Pain is Poorly Controlled by NSAIDs
• [48] KC706, an Oral p38 MAP Kinase Inhibitor, Increases HDL-C. Circulation. 2007;116:II_126.
• [49] Synthesis and structure-activity relationship of aminobenzophenones. A novel class of p38 MAP kinase inhibitors with high antiinflammatory activity. J Med Chem. 2003 Dec 18;46(26):5651-62.
• [50] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [51] A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469.Pharmacogenet Genomics.2014 Feb;24(2):129-32.
• [52] XK469, a selective topoisomerase IIbeta poison. Proc Natl Acad Sci U S A. 1999 October 12; 96(21): 12168-12173.
• [53] Design of new topoisomerase II inhibitors based upon a quinobenzoxazine self-assembly model. J Med Chem. 1998 Oct 22;41(22):4273-8.
• [54] Phosphatidylinositol 4,5-bisphosphate rescues TRPM4 channels from desensitization. J Biol Chem. 2005 Nov 25;280(47):39185-92.
• [55] Decavanadate modulates gating of TRPM4 cation channels. J Physiol. 2004 Nov 1;560(Pt 3):753-65.
• [56] A pyrazole derivative potently inhibits lymphocyte Ca2+ influx and cytokine production by facilitating transient receptor potential melastatin 4 ch... Mol Pharmacol. 2006 Apr;69(4):1413-20.
• [57] 9-phenanthrol inhibits human TRPM4 but not TRPM5 cationic channels. Br J Pharmacol. 2008 Apr;153(8):1697-705.
• [58] DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
• [59] Substituted benzyl-pyrimidines targeting thymidine monophosphate kinase of Mycobacterium tuberculosis: synthesis and in vitro anti-mycobacterial ac... Bioorg Med Chem. 2008 Jun 1;16(11):6075-85.
• [60] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [61] Etoposide, topoisomerase II and cancer.Curr Med Chem Anticancer Agents.2005 Jul;5(4):363-72.
• [62] Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6.
• [63] Inhibition of human topoisomerase IIalpha by fluoroquinolones and ultraviolet A irradiation. Toxicol Sci. 2002 Sep;69(1):16-22.
• [64] Antitumor properties of podophyllotoxin and related compounds. Curr Pharm Des. 2000 Dec;6(18):1811-39.
• [65] Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121.
• [66] Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010 Nov 18;363(21):1991-2003. doi: 10.1056/NEJMoa0909825.
• [67] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [68] Adenosine receptors and phosphodiesterase inhibitors stimulate Cl- secretion in Calu-3 cells. Am J Respir Cell Mol Biol. 2003 Sep;29(3 Pt 1):410-8. doi: 10.1165/rcmb.2002-0247OC. Epub 2003 Apr 24.
• [69] Modulation of deltaF508 cystic fibrosis transmembrane regulator trafficking and function with 4-phenylbutyrate and flavonoids. Am J Respir Cell Mol Biol. 2004 Sep;31(3):351-7. doi: 10.1165/rcmb.2002-0086OC. Epub 2004 Jun 10.
• [70] Proteasome-dependent pharmacological rescue of cystic fibrosis transmembrane conductance regulator revealed by mutation of glycine 622. J Pharmacol Exp Ther. 2008 Apr;325(1):89-99. doi: 10.1124/jpet.107.134502. Epub 2008 Jan 29.
• [71] Comparative pharmacology of the activity of wild-type and G551D mutated CFTR chloride channel: effect of the benzimidazolone derivative NS004. J Membr Biol. 2003 Jul 15;194(2):109-17. doi: 10.1007/s00232-003-2030-z.
• [72] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [73] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [74] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [75] Alternaria toxins as casein kinase 2 inhibitors and possible consequences for estrogenicity: a hybrid in silico/in vitro study. Arch Toxicol. 2020 Jun;94(6):2225-2237. doi: 10.1007/s00204-020-02746-x. Epub 2020 Apr 23.
• [76] Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer. J Med Chem. 2011 Jan 27;54(2):635-54.
• [77] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [78] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [79] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [80] Capsaicin, a component of red peppers, stimulates protein kinase CKII activity. BMB Rep. 2010 May;43(5):325-9. doi: 10.5483/bmbrep.2010.43.5.325.
• [81] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.